Controlled M1-to-M2 transition of aged macrophages by calcium phosphate coatings

• Published in: Biomaterials 2019-03, Vol.196, p.90-99
• Main Authors: Alhamdi, Jumana R., Peng, Tao, Al-Naggar, Iman M., Hawley, Kelly L., Spiller, Kara L., Kuhn, Liisa T.
• Format: Article
• Language: English
• Subjects: Aging; Animals; Bone repair; Calcium phosphate; Calcium Phosphates - pharmacology; Cellular Senescence - drug effects; Coated Materials, Biocompatible - pharmacology; Dose-Response Relationship, Drug; Drug delivery; Drug Delivery Systems; Gene Expression Regulation - drug effects; Humans; Interferon-gamma - pharmacology; Kinetics; Macrophages; Macrophages - cytology; Macrophages - drug effects; Macrophages - metabolism; Male; Mice, Inbred C57BL; Simvastatin; Simvastatin - pharmacology; THP-1 Cells; Time Factors
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2018.07.012

Older adults suffer from weakened and delayed bone healing due to age-related alterations in bone cells and in the immune system. Given the interaction between the immune system and skeletal cells, therapies that address deficiencies in both the skeletal and the immune system are required to effectively treat bone injuries of older patients. The sequence of macrophage activation observed in healthy tissue repair involves a transition from a pro-inflammatory state followed by a pro-reparative state. In older patients, inflammation is slower to resolve and impedes healing. The goal of this study was to design a novel drug delivery system for temporal guidance of the polarization of macrophages using bone grafting materials. A biomimetic calcium phosphate coating (bCaP) physically and temporally separated the pro-inflammatory stimulus interferon-gamma (IFNγ) from the pro-reparative stimulus simvastatin (SIMV). Effective doses were identified using a human monocyte line (THP-1) and testing culminated with bone marrow macrophages obtained from old mice. Sequential M1-to-M2 activation was achieved with both cell types. These results suggest that this novel immunomodulatory drug delivery system holds potential for controlling macrophage activation in bones of older patients.